Tamara Tanner
<p>Tamara I. Tanner, MD, is Assistant Director of the Pediatric Rheumatology Fellowship Program and an attending physician of pediatric rheumatology at the Children’s Hospital at Montefiore Einstein (CHAM). She is also an Assistant Professor of Pediatrics at our Albert Einstein College of Medicine.</p>Dr. Tanner earned her Bachelor of Arts in 1999 at University of Bucharest, Romania. After completing her Master of Arts at Yeshiva University in New York in 2009 and post-baccalaureate premedical courses at Hunter College in 2010, Dr. Tanner attended New York Medical College, earning her Doctor of Medicine in 2014. She pursued her postdoctoral training at CHAM, completing a three-year pediatric residency in 2017 followed by a three year pediatric rheumatology fellowship in 2020.<br /><br />Dr. Tanner’s clinical focus is on the care of children with complex rheumatologic diseases including juvenile idiopathic arthritis, systemic lupus erythematosus, juvenile dermatomyositis, vasculitis, scleroderma and periodic fever syndromes. In addition to her strong background in medical education, she has a research focus on risk factors for lupus flares, as well as investigations in macrophage activation syndrome. Dr. Tanner is board certified in general pediatrics, and is a member of the American College of Rheumatology and the Childhood Arthritis and Rheumatology Research Alliance. In 2020, Dr. Tanner was inducted into the Leo M. Davidoff Society in recognition of her outstanding achievement in teaching medical students.<p> </p>
Brian D. Spund
Theresa M. Serra
Pediatric Medicine
<p class="MsoNormal">Theresa Serra, MD, joined the CHAM hospitalist division in 2014 after working as a pediatric hospitalist at New York Presbyterian/Lower Manhattan Hospital. Her interests include clinical research and medical education. She has conducted an IRB approved retrospective chart review examining readmission rates in pediatric patients diagnosed with osteomyelitis. Dr. Serra is currently developing a medical Spanish curriculum for faculty members in order to improve communication between patients, families and providers. Along with Courtney McNamara, MD, Dr. Serra is a co-leader of a multidisciplinary committee dedicated to standardizing and improving quality of care for patients hospitalized with the diagnosis of failure to thrive. Dr. Serra is also working on an initiative to identify vaccine delinquency in the inpatient setting through the use of SMART reports.</p> <p class="MsoNormal">Dr. Serra is also collaborating with Lindsey Douglas, MD, MSCR, in an IRB approved quality improvement (QI) project to improve transition-of-care communication between hospitalists and primary care providers and to facilitate the establishment of medical homes. Dr. Serra is also a member of a subcommittee that leads monthly journal clubs/case conferences for pediatric hospitalists.</p>
Amrita K. Seehra
Alejandra I. Sacasa
Evelyn M. Rondinel
Molly O. Regelmann
Pediatric Endocrinology
<p>Dr. Regelmann is an Assistant Professor of Pediatric Endocrinology and Diabetes at the Children’s Hospital at Montefiore. She formerly held the same position at the Icahn School of Medicine at Mount Sinai, where she established herself for clinical excellence, being named a New York Rising Stars Super Doctor and Castle Connolly Top Doctor.</p><p>Dr. Regelmann graduated magna cum laude with high honors in research from Cornell University. She received her medical education at New York University. She completed residency training in general pediatrics and fellowship training in pediatric endocrinology at the Icahn School of Medicine at Mount Sinai.</p>
Allison K. Paul
Shadi Nahvi
<p>Dr. Shadi Nahvi is Professor (with tenure) in the Departments of Medicine and Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine, and directs the General Internal Medicine and Addiction Medicine Fellowship Programs. Her research focuses on optimizing quality of life and health outcomes among persons with substance use disorder.</p>
<p>Dr. Nahvi’s research is grounded in nearly two decades of clinical experience as a primary care physician caring for persons with opioid and other substance use disorders. Her primary research focus is optimizing the efficacy and delivery of tobacco cessation treatments among persons with co-occurring substance use disorders. Currently, she is Principal Investigator of a NIDA R01-funded randomized, 2 x 2 factorial trial of directly observed and long-term varenicline treatment among smokers with opioid use disorder. She has also led a KL2 Career Development Award-funded, randomized, placebo-controlled pilot trial of varenicline for smoking cessation among smokers with co-morbid substance use disorder, a study of health system-level interventions to increase documentation and treatment of tobacco use among substance use disorder counselors, and a randomized trial of the efficacy of directly observed varenicline provided at a methadone clinic for promoting smoking cessation and enhancing adherence. </p>
<p>Dr. Nahvi graduated from the Brown University School of Medicine in 2001 and completed residency training in Primary Care Internal Medicine at Bellevue Hospital and New York University Medical Center in 2004. She then joined the faculty in the Albert Einstein College of Medicine Division of Substance Abuse as the Medical Director of an opioid treatment program.</p>
<p>Dr. Nahvi has served on numerous national advisory committees, including serving as a member of the NY State Department of Health AIDS Institute’s Guideline Committee for the Care of Substance Users and a Steering Committee member of the NY State Department of Health AIDS Institute's Tobacco Cessation Improvement Campaign.</p>
* Improving health outcomes and quality of life of persons with substance use disorders
<p>Selected recent publications:</p>
<p>Nahvi S, Segal KS, Litwin AH, Arnsten JH. Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinics. <em>Addiction Science and Clinical Practice. </em>2014, 13;9:9</p>
<p class="Normal">Nahvi S, Blackstock O, Sohler NL, Thompson D, Cunningham CO. Smoking cessation treatment among office-based buprenorphine treatment patients. <em>Journal of Substance Abuse Treatment. </em>2014, 47(2):175-9</p>
<p>Nahvi S, Ning Y, Segal KS, Richter KP, Arnsten JH. Varenicline efficacy and safety among methadone maintained smokers: A randomized placebo-controlled trial. <em>Addiction. </em>2014, 109(9):1554-63</p>
<p>Griffin J, Segal KS, Arnsten JH, Nahvi S. Barriers to telephone quitline use among methadone maintained smokers. <em>Nicotine & Tobacco Research.</em> 2015,17(8):931-6</p>
<p>Batchelder AW, Peyser D, Nahvi S, Arnsten JH, Litwin AH. "Hepatitis C treatment turned me around:" Psychological and behavioral transformation related to Hepatitis C treatment. <em>Drug and Alcohol Dependence.</em> 2015, 153:66-71</p>
<p>Maradiaga J, Nahvi S, Cunningham CO, Sanchez J, Fox AD. "I kicked the hard way. I got incarcerated." Withdrawal from methadone during incarceration and subsequent aversion to medication assisted treatments. <em>Journal of Substance Abuse Treatment.</em> 2016, 62:49-54</p>
<p>Fitzgerald SA, Faseru B, Mussulman L, Howser E, Nahvi S, Goggin K, Cooperman NA, Richter KP. Improving quality of care for hospitalized smokers with HIV: Tobacco dependence treatment referral and utilization. <em>The Joint Commission Journal on Quality and Patient Safety.</em> 2016, 42(5):219-24</p>
<p>Shah PA, Cunningham CO, Blackstock OJ, Brisbane MT, Nahvi S. Use of smoking cessation methods among patients receiving office-based buprenorphine maintenance treatment. <em>Journal of Addiction Medicine.</em> 2017, 11(6):494-497</p>
<p>Adams TR, Arnsten JH, Ning Y, Nahvi S. Feasibility and preliminary effectiveness of varenicline for treating co-occurring cannabis and tobacco use. <em>Journal of Psychoactive Drugs.</em> 2018, 50(1):12-18</p>
<p>Sohler NL, Starrels J, Khalid L, Bachhuber M, Arnsten JH, Nahvi S, Jost J, Cunningham CO. Marijuana use is associated with lower odds of prescription opioid analgesic use among HIV-infected individuals with chronic pain. <em>Substance Use and Misuse. </em>2018, 17:1-6</p>
<p>Minami H, Brinkman HR, Nahvi S, Arnsten JH, Rivera-Mindt M, Wetter DW, Litvin Bloom E, Price LH, Vieira C, Donnelly R, McClain LM, Kennedy KA, D'Aquila E, Fine M, McCarthy DE, Thomas JG, Hecht J, Brown RA. Rationale, design and pilot feasibility results of a smartphone-assisted, mindfulness-based intervention for smokers with mood disorders: Project mSMART MIND. <em>Contemporary Clinical Trials. </em>2018, 66:26-44</p>
<p>Weinberger AH, Pacek LR, Wall MM, Zvolensky MJ, Copeland J, Galea S, Nahvi S, Moeller SJ, Hasin DS, Goodwin RD. Trends in cannabis use disorder by cigarette smoking status in the United States, 2002 to 2016. <em>Drug and Alcohol Dependence.</em> 2018, 191:45-51</p>
<p>Nahvi S, Arnsten JH. Missed opportunities to test the neuropsychiatric safety--and efficacy--of varenicline among smokers with substance use disorders. <em>Drug and Alcohol Dependence. </em>2018, 185: 245-247.</p>